In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 202-207

  Hagihara, Mao ^a,b   Wiskirchen, Dora E ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEFAZOLIN; COLONY COUNT, MICROBIAL; CULTURE MEDIA; DRUG INTERACTIONS; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84455173055     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05473-11     Document Type: Article

References (39)

1. Albrecht LM, Rybak MJ, Warbasse LH, Edwards DJ. 1991. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25:713-715.
2. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl A):125-130. (Pubitemid 15079556)
3. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. (Pubitemid 38200128)
4. Climo MW, Patron RL, Archer GL. 1999. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob. Agents Chemother. 43:1747-1753. (Pubitemid 29331259)
5. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7, vol 26, no 2. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
7. Domenech A, et al. 2005. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 56:709-716. (Pubitemid 41487773)
8. Dudley MN, Nightingale CH, Drezner AD, Low HB, Quintiliani R. 1984. Comparative penetration of cefonicid and cefazolin into the atrial appendage and pericardial fluid of patients undergoing open-heart surgery. Antimicrob. Agents Chemother. 26:347-350. (Pubitemid 14006022)
9. Dudley M, et al. 1999. Pharmacokinetic-pharmacodynamic indices for vancomycin treatment of susceptible and intermediate S. aureus in the neutropenic mouse thigh model, abstr 2031, p 49. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287. (Pubitemid 27231427)
11. Fox PM, Lampen RJ, Stumpf KS, Archer GL, Climo MW. 2006. Successful therapy of experimental endocarditis caused by vancomycinresistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics. Antimicrob. Agents Chemother. 50:2951-2956. (Pubitemid 44396397)
12. Gold JA, McKee JJ, Ziv DS. 1973. Experience with cefazolin: an overall summary of pharmacologic and clinical trials in man. J. Infect. Dis. 128:S415-S421.
13. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. 1987. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 31:393-397. (Pubitemid 17027127)
14. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144. (Pubitemid 44631403)
15. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047. (Pubitemid 44396410)
16. Howden BP, et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528. (Pubitemid 38250962)
17. Jorgenson L, et al. 2007. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr. Neurosurg. 43:449-455. (Pubitemid 350085281)
18. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
19. Lamer C, et al. 1993. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. 37:281-286. (Pubitemid 23046569)
20. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672. (Pubitemid 39577670)
21. Lodise TP, et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
22. MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE. 2011. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 55:867-873.
23. Moise PA, Sakoulas G, Forrest A, Schentag JJ. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586. (Pubitemid 47047340)
24. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942. (Pubitemid 39447034)
25. Ornelas-Soares A, de Lencastre H, de Jonge BLM, Tomasz A. 1994. Reduced methicillin resistance in a new Staphylococcus aureus transposon mutant that incorporates muramyl dipeptides into the cell wall peptidogylcan. J. Biol. Chem. 269:27246-27250. (Pubitemid 24346541)
26. Rhee KY, Gardiner DF, Charles M. 2005. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin. Infect. Dis. 40:1705-1706. (Pubitemid 40720831)
27. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F. 2000. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 44:3055-3060.
28. Rose WE, Poppens PT. 2009. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63:485-488.
29. Sakoulas G, et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. (Pubitemid 38747480)
30. Severin A, Wu SW, Tabei K, Tomasz A. 2004. Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the enterococcal vanA gene complex. Antimicrob. Agents Chemother. 48:4566-4573. (Pubitemid 39577655)
31. Sieradzki K, Tomasz A. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566. (Pubitemid 27164554)
32. Sieradzki K, Tomasz A. 1997. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J. Antimicrob. Chemother. 39:S47-S51.
33. Skhirtladze K, et al. 2006. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob. Agents Chemother. 50:1372-1375.
34. Small PM, Chambers HF. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227-1231. (Pubitemid 20177385)
35. Smyth RD, Pfeffer M, Glick A, Van Harken DR, Hottendorf GH. 1979. Clinical pharmacokinetics and safety of high doses of ceforanide (BLS786R) and cefazolin. Antimicrob. Agents Chemother. 16:615-621. (Pubitemid 10165197)
36. Soriano A, et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200. (Pubitemid 351269157)
37. Steinkraus G, White R, Friedrich L. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Agents Chemother. 60:788-794. (Pubitemid 47434257)
38. Turner J, et al. 2001. The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model. J. Antimicrob. Chemother. 48:727-730. (Pubitemid 33100321)
39. Wang G, Hindler JF, Ward KW, Bruckner DA. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886. (Pubitemid 44737223)